2-(ethylthio)-6,7-difluoro-4-hydroxy-3-quinolinecarboxylic acid ethyl ester is a fluorinated quinoline-3-carboxylate intermediate with the molecular formula C₁₄H₁₃F₂NO₃S and a formula weight of 313.32 g/mol. The substitution pattern includes a C2 ethylthio group, C6 and C7 fluorine atoms, a C4 hydroxyl group, and a C3 ethyl ester. This arrangement places the compound within the broader 4-hydroxyquinoline-3-carboxylate family used in registered synthetic routes for active pharmaceutical ingredients, but published data specific to this exact intermediate configuration is limited. When supplied as a pharmaceutical-grade material for tablet, capsule, granule, oral liquid, and injectable manufacturing, the product is released under a batch-specific certificate of analysis that references ICH Q6A control elements, residual solvent testing according to ICH Q3C(R8), elemental impurity control under ICH Q3D, and the current good manufacturing practice expectations of 21 CFR 210 and 211. The material is handled as a controlled powder; primary packaging is selected to limit moisture ingress and oxygen exposure because both the ethyl ester and the ethylthio group are sensitive to hydrolytic and oxidative degradation pathways under common processing conditions.

The material is supplied under a manufacturer-specific article code and is available in non-micronized and micronized grades. The exact model designation, particle size grade, and packaging configuration are stated on the certificate of analysis. No official pharmacopoeial monograph exists under this exact chemical name, so the article code, route of synthesis, and batch-specific acceptance criteria form the control identity. Packaging configurations for high-potency or sensitizing quinoline intermediates typically use double polyethylene liners inside aluminum-laminated foil drums; if the material is classified as a potent or sensitizing compound, containment should follow the occupational exposure band assigned by the manufacturer.

Specification data are provided for each batch and include appearance, identity, assay, related substances, residual solvents, water, residue on ignition, elemental impurities, and particle size. The validated HPLC assay reports the active content on an anhydrous, solvent-free basis; the assigned acceptance range is stated in the certificate of analysis. The material should not be released without complete documentation because the impurity profile depends on the final crystallization conditions.

What limits processing of the C3 ethyl ester in aqueous granulation and injectable formulation?

The C3 ethyl ester functions as a protected carboxyl group. Under alkaline aqueous conditions, saponification to the free carboxylic acid can occur; therefore, wet granulation with water or water-containing binders should be maintained below pH 7 when ester integrity is required for downstream synthesis or final product stability. In high-shear granulators, local pH generated by buffer salts, filler alkalinity, or binder solutions must be controlled because the granule microenvironment can drive ester cleavage even when the bulk granulating fluid is only mildly alkaline. If aqueous processing is unavoidable, granulation end-point should be monitored by in-process HPLC rather than torque or power draw alone; the method should be validated for specificity according to USP <1225> and Ph. Eur. 2.2.46. Non-aqueous granulation using anhydrous ethanol or isopropanol, followed by vacuum drying, may be used if the batch CoA indicates thermal stability above the drying temperature. Fluid-bed drying temperature should be set below the onset temperature observed in differential scanning calorimetry; published data for this specific compound is limited, so the onset must be confirmed on a representative batch before scale-up.

For injectable dosage forms, the main processing limits are moisture, heat, and oxygen. Terminal sterilization using moist heat exposes the molecule to hydrolytic conditions; aseptic processing with subsequent lyophilization is often preferred for ester-containing APIs if thermal and aqueous stability are not demonstrated. During solution preparation, the ethylthio group may oxidize to the corresponding sulfoxide or sulfone under oxidative stress. Nitrogen blanketing and control of headspace oxygen in vials are recommended, and the stopper moisture content should be dried to a level consistent with the approved stability protocol. Filtration through a sterilizing-grade membrane with a pore size of 0.22 µm is typical for injectable manufacturing, but filter compatibility with the organic cosolvent and any buffering agent must be confirmed because fluorinated aromatic compounds can interact with certain nylon membranes.

For tablet and capsule lines, the API is blended with excipients in a bin blender or tumble blender; the blender fill fraction is checked because cohesive powders may segregate if the fill volume is too low. A high-shear granulator with impeller tip speed between 2 m/s and 10 m/s is typical for wet granulation, but the exact speed is product-specific. Roller compaction for dry granulation uses roll pressure and gap settings established by ribbon density measurement; the resulting granules are milled through a screen suitable for tablet compression. Capsule filling may be performed by dosator or tamping pin machines; the powder should meet flow and compressibility requirements under USP <1174>.

Release data for commercial batches are generated by high-performance liquid chromatography on a reversed-phase C18 column with UV detection. The method is validated for specificity, linearity, accuracy, and precision according to USP <1225> and Ph. Eur. 2.2.46. Because sulfur-containing degradants and the difluoroquinoline core may have different UV response factors, relative response factors should be determined for known impurities and used for area normalization instead of simple percent area when the impurity profile includes oxidative by-products. Residual solvent testing follows USP <467> or Ph. Eur. 2.4.24. If the final crystallization is performed from ethyl acetate or ethanol, the corresponding ICH Q3C(R8) Class 3 limit of 5000 ppm applies unless a higher level is justified by the applicant. Water content is determined by Karl Fischer titration according to USP <921> Method 1a or Ph. Eur. 2.5.12. Elemental impurities are screened by inductively coupled plasma mass spectrometry according to USP <233> and limits are set in accordance with ICH Q3D for the intended route of administration. Identity is confirmed by infrared absorption against a qualified reference standard according to Ph. Eur. 2.2.24 or USP <197>, and the absence of residual inorganic salts is controlled by sulfated ash or residue on ignition according to Ph. Eur. 2.4.14. For an active substance with a maximum daily dose of 2 g/day or less, the ICH Q3A(R2) thresholds are 0.05% for reporting, 0.10% for identification, and 0.15% for qualification; these thresholds should be applied to the impurity profile unless the final dosage form has a lower daily intake.

When the C2 ethylthio and C6/C7 difluoro motif is compared with piperazinyl fluoroquinolones

The most significant structural differences from widely used fluoroquinolone APIs are the absence of a piperazine substituent at C7 and the retention of the C3 ethyl ester. Ciprofloxacin and norfloxacin carry a 7-piperazinyl group and a free 3-carboxylic acid, whereas this compound carries fluorine at both C6 and C7 and a protected acid function. In a registered synthetic pathway, the C3 ester is maintained to control the acid center until a later hydrolysis or activation step, while the 4-hydroxy group can tautomerize with the adjacent ester carbonyl and participate in metal binding. The C2 ethylthio group introduces a sulfur atom not present in most commercial fluoroquinolone APIs and will alter reversed-phase retention, UV absorption, and oxidative lability relative to C2-hydrogen or C2-methyl analogs. These structural differences mean that the material should be treated as an intermediate or a synthetic scaffold rather than as a direct substitute for finished fluoroquinolone APIs; a change in this position should not be assumed to produce an equivalent impurity profile or process compatibility.

Compared with the corresponding 2-methylthio and 2-phenylthio derivatives, the ethylthio group is smaller and may provide different reactivity in nucleophilic displacement or oxidation. Compared with the 6-fluoro-7-piperazinyl analogs, this difluoro pattern leaves the 7-position available for further substitution while the C3 ester protects the acid function. These are structural considerations only; the performance of the compound in a specific synthetic step must be verified experimentally and cannot be inferred from the substitution pattern alone.

Differences from other suppliers of the same nominal chemical should not be assessed by HPLC purity alone. Polymorphic form, residual solvent profile, particle size distribution, and trace metal content can vary depending on the synthetic route, final crystallization solvent, and drying conditions. A supplier qualification audit should compare the route of synthesis, final crystallization, and residual impurity profile, not solely the certificate of analysis. For oral solid dosage processing, batch-to-batch particle size variation is a practical bottleneck because it affects blend uniformity and segregation during compression. If the material is intended for direct compression or dry granulation, a particle size specification by laser diffraction under USP <429> should be included, and the powder flow character should be assessed according to USP <1174> or Ph. Eur. 2.9.16.

Because quinoline intermediates with multiple halogens and a sulfur substituent may require dust containment, weighing and dispensing are carried out in downward-flow booths or isolators, and operators use air-purifying respirators when occupational exposure limits have not been established. For oral solid dose blending, a bin blender operating at 50% to 70% of rated capacity reduces segregation; this is standard powder handling practice, but published data for this specific compound is limited. If wet granulation is selected, a high-shear mixer impeller and chopper speed should be set to avoid overgranulation, and the granulate should be dried to a moisture endpoint consistent with the release specification. Dry granulation by roller compaction may be preferred when the ester function is sensitive to moisture. For injectable processing, dissolution in a non-aqueous cosolvent system, filtration through a 0.22 µm sterilizing-grade membrane, and lyophilization are typical, but the finished formulation must be validated under ICH Q8 and ICH Q9 because the compound is lipophilic and has low aqueous solubility. Oral liquid formulations may require pH adjustment or cosolvents such as polyethylene glycol or propylene glycol within compendial limits; the applicant is responsible for establishing the final shelf-life and storage conditions under ICH Q1A(R2).

Injectable formulation development should evaluate solvent systems that are acceptable under 21 CFR 314.94 for parenterals; for example, polyethylene glycol 300, propylene glycol, ethanol, and water for injection may be combined within compendial limits. The compound should be protected from light during manufacturing because fluorinated quinolone derivatives may undergo photodegradation; ICH Q1B photostability testing should be conducted on the formulated solution and lyophilized cake. If terminal sterilization is not possible, aseptic filtration followed by lyophilization is used; the filling line should be designed to minimize oxygen exposure and the vials should be flushed with nitrogen before sealing.

Hydrolysis, oxidation, and terminal sterilization sensitivities

Forced degradation studies conducted under ICH Q1A(R2) should be used to demonstrate the stability-indicating capability of the HPLC method. The ester substituent is most sensitive to alkaline hydrolysis, while the ethylthio group is susceptible to oxidation under peroxide or oxygen-rich conditions. Acid degradation may lead to C2 thioether protonation and ester acid hydrolysis; separate stress conditions at pH 1, pH 7, and pH 10 in combination with heat and light exposure should be evaluated. Because the compound contains a sulfur atom, oxidative stress using 3% hydrogen peroxide is commonly used, but published data for this specific configuration is limited. The resulting sulfoxide or sulfone impurities should be identified by liquid chromatography–mass spectrometry and included in the specification if observed above the qualification threshold under ICH Q3A(R2).

For thermal processing, differential scanning calorimetry and thermogravimetric analysis should be used to determine the onset of decomposition, and manufacturing equipment should be operated below that onset with a validated margin. Lyophilization cycles should be designed to keep the product below the collapse temperature; the ester and sulfur groups are not necessarily sources of collapse but may degrade if the freeze-dried cake is exposed to residual moisture or oxygen. Containers for bulk storage should be double polyethylene-lined with an aluminum foil barrier, and bulk repackaging should be performed under nitrogen if oxidative degradation is confirmed. The product should not be milled in a high-energy mill without inert gas cooling if the powder is heat-labile; a pin mill or cone mill with controlled rotor speed is preferred for size reduction.

Cleaning validation in multipurpose pharmaceutical facilities should account for the sulfur- and fluorine-containing organic residue and any oxidative by-products. Swab and rinse sampling sites include mixer walls, discharge valves, micronizer surfaces, and tablet press feed frames. Acceptance limits are derived from the permitted daily exposure and the next-product batch size, not from a fixed ppm value alone. For compounds without published toxicological limits, a default permitted daily exposure may be used according to the company's quality risk management under ICH Q9, but published toxicological data for this specific configuration is limited. Because the ethylthio group can produce odor-active sulfur species during degradation, equipment should be cleaned without high-pH detergents that could accelerate ester saponification and release sulfur-containing residues. Dedicated or campaign manufacturing may be considered for injectable lines.